Trials / Terminated
TerminatedNCT00809510
A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 55 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-089 | 20 mg ABT-089 taken once-daily for 6 months |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-06-01
- First posted
- 2008-12-17
- Last updated
- 2011-09-02
Locations
22 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00809510. Inclusion in this directory is not an endorsement.